You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 164 No. 18, October 11, 2004 TABLE OF CONTENTS
  Archives
  •  Online Features
  Review Article
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (47)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Women's Health
 •Women's Health, Other
 •Review
 •Venous Thromboembolism
 •Alert me on articles by topic

Risk of Venous Thromboembolic Disease Associated With Hormonal Contraceptives and Hormone Replacement Therapy

A Clinical Review

Marcelo P. V. Gomes, MD; Steven R. Deitcher, MD

Arch Intern Med. 2004;164:1965-1976.

Venous thromboembolic events (VTEs) represent a serious complication related to hormonal contraception and hormone replacement therapy (HRT). Evidence on hormonal contraceptive– and HRT-related VTEs is derived almost exclusively from observational studies and points to a 2- to 6-fold increased relative risk of VTEs with either therapy. Oral contraceptive pills that contain third-generation progestins (desogestrel or gestodene) seem to be associated with greater VTE risk than those that contain levonorgestrel. Oral contraceptive pill use and HRT are associated with exponentially higher VTE relative risks when used by women who carry an inherited hypercoagulable state. The indication of a lower or a lack of VTE risk associated with the use of progestin-only contraceptives and with transdermal HRT suggests that these therapies may be safer than combination oral contraceptive pills and oral HRT for women in whom oral estrogen therapy is considered contraindicated. Data that support such safety advantages are limited and should be interpreted with caution.


From the Section of Hematology and Coagulation Medicine, Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Cleveland, Ohio. The authors have no relevant financial interest in this article.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Venous thromboembolism in women
Rathbun
Vasc Med 2008;13:255-266.
ABSTRACT  

Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis
Canonico et al.
BMJ 2008;336:1227-1231.
ABSTRACT | FULL TEXT  

The Epidemiology of Venous Thromboembolism in the Community
Heit
Arterioscler. Thromb. Vasc. Bio. 2008;28:370-372.
FULL TEXT  

Review: Contraception in adolescents with systemic lupus erythematosus
Tincani et al.
Lupus 2007;16:600-605.
ABSTRACT  

Suppression of menstruation in adolescents with severe learning disabilities
Albanese and Hopper
Arch. Dis. Child. 2007;92:629-632.
ABSTRACT | FULL TEXT  

2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Authors/Task Force Members: et al.
Eur Heart J 2007;0:ehm236v1-75.
FULL TEXT  

Are Some Types of Hormone Therapy Safer Than Others?: Lessons From the Estrogen and Thromboembolism Risk Study
Rexrode and Manson
Circulation 2007;115:820-822.
FULL TEXT  

A 27-Year-Old Woman With a Diagnosis of Polycystic Ovary Syndrome
Legro
JAMA 2007;297:509-519.
ABSTRACT | FULL TEXT  

Thrombophilia: Common Questions on Laboratory Assessment and Management
Heit
ASH Education Book 2007;2007:127-135.
ABSTRACT | FULL TEXT  

Conjugated Equine Estrogen, Esterified Estrogen, Prothrombotic Variants, and the Risk of Venous Thrombosis in Postmenopausal Women
Smith et al.
Arterioscler. Thromb. Vasc. Bio. 2006;26:2807-2812.
ABSTRACT | FULL TEXT  

Management of Menopausal Symptoms
Grady
NEJM 2006;355:2338-2347.
FULL TEXT  

Complex Actions of Sex Steroids in Adipose Tissue, the Cardiovascular System, and Brain: Insights from Basic Science and Clinical Studies
Turgeon et al.
Endocr. Rev. 2006;27:575-605.
ABSTRACT | FULL TEXT  

Venous thromboembolism
Blann and Lip
BMJ 2006;332:215-219.
FULL TEXT  

Management of Hereditary Hypercoagulable Disorders
Bockenstedt
ASH Education Book 2006;2006:444-449.
ABSTRACT | FULL TEXT  

A Trial of Contraceptive Methods in Women with Systemic Lupus Erythematosus
Sanchez-Guerrero et al.
NEJM 2005;353:2539-2549.
ABSTRACT | FULL TEXT  

Prothrombotic Mutations, Hormone Therapy, and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration
Straczek et al.
Circulation 2005;112:3495-3500.
ABSTRACT | FULL TEXT  

Estrogen Plus Progestin and Risk of Venous Thrombosis
Scarabin et al.
JAMA 2005;293:1322-1322.
FULL TEXT  

Estrogen Plus Progestin, Benefits and Risks: The "Women's Health Initiative" Trials
Keller and Lemberg
Am J Crit Care 2005;14:157-160.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.